Prior colonisation with Candida species fails to guide empirical therapy for candidaemia in critically ill adults.

[1]  S. Blot,et al.  Management of Invasive Candidiasis in Critically Ill Patients , 2012, Drugs.

[2]  J. Nolla,et al.  Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[3]  Jordi Rello,et al.  Is Candida really a threat in the ICU? , 2008, Current opinion in critical care.

[4]  P. Hsueh,et al.  Candida glabrata fungaemia in intensive care units. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  A. Webster,et al.  Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. , 2006, The Journal of antimicrobial chemotherapy.

[6]  J. Garnacho-Montero,et al.  A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization* , 2006, Critical care medicine.

[7]  Michael Y. Lin,et al.  Prior Antimicrobial Therapy and Risk for Hospital-Acquired Candida glabrata and Candida krusei Fungemia: a Case-Case-Control Study , 2005, Antimicrobial Agents and Chemotherapy.

[8]  R. Piarroux,et al.  Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients(*) , 2004, Critical care medicine.

[9]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Pittet,et al.  Management of candidiasis Management of Candida species infections in critically ill patients , 2003 .

[11]  D. Pittet,et al.  Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. , 2003, The Lancet. Infectious diseases.

[12]  W. Powderly,et al.  A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Pittet,et al.  Management of Candida species infections in critically ill patients. , 2003, The Lancet. Infectious diseases.

[14]  F. Colardyn,et al.  Effects of nosocomial candidemia on outcomes of critically ill patients. , 2002, The American journal of medicine.

[15]  B. Guidet,et al.  Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. , 2002, Journal of critical care.

[16]  R. Gaynes,et al.  Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  E. Anaissie,et al.  Revisiting the source of candidemia: skin or gut? , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Pfaller,et al.  International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program , 2001, Journal of Clinical Microbiology.

[19]  L. Saiman,et al.  Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  F. Colardyn,et al.  Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata. , 2001, The Journal of hospital infection.

[21]  E. Bouza,et al.  Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. , 2000, International journal of antimicrobial agents.

[22]  P. Lipsett,et al.  The diagnostic value of fungal surveillance cultures in critically ill patients. , 2000, Surgical infections.

[23]  M. A. Martin,et al.  National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. , 1998, Diagnostic microbiology and infectious disease.

[24]  D. Snydman,et al.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.

[25]  J. Vincent,et al.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. , 1995, JAMA.

[26]  R. Wenzel,et al.  Evidence of nosocomial spread of Candida albicans causing bloodstream infection in a neonatal intensive care unit. , 1995, Diagnostic microbiology and infectious disease.

[27]  R. Auckenthaler,et al.  Candida Colonization and Subsequent Infections in Critically III Surgical Patients , 1994, Annals of surgery.

[28]  G. Slotman,et al.  Fungal sepsis: multisite colonization versus fungemia. , 1994, The American surgeon.

[29]  J. Sobel,et al.  Nosocomial acquisition of Candida albicans: an epidemiologic study. , 1993, The Journal of infectious diseases.

[30]  R. Wenzel,et al.  Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe , 1990, Journal of clinical microbiology.

[31]  J. Solomkin,et al.  Indications for therapy for fungemia in postoperative patients. , 1982, Archives of surgery.

[32]  P. Ashworth.  In the intensive care unit. , 1978, Nursing mirror.